1. Home
  2. IIF vs ALLO Comparison

IIF vs ALLO Comparison

Compare IIF & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IIF
  • ALLO
  • Stock Information
  • Founded
  • IIF 1993
  • ALLO 2017
  • Country
  • IIF United States
  • ALLO United States
  • Employees
  • IIF N/A
  • ALLO N/A
  • Industry
  • IIF Trusts Except Educational Religious and Charitable
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • IIF Finance
  • ALLO Health Care
  • Exchange
  • IIF Nasdaq
  • ALLO Nasdaq
  • Market Cap
  • IIF 272.7M
  • ALLO 277.8M
  • IPO Year
  • IIF N/A
  • ALLO 2018
  • Fundamental
  • Price
  • IIF $28.11
  • ALLO $1.22
  • Analyst Decision
  • IIF
  • ALLO Strong Buy
  • Analyst Count
  • IIF 0
  • ALLO 9
  • Target Price
  • IIF N/A
  • ALLO $8.44
  • AVG Volume (30 Days)
  • IIF 45.4K
  • ALLO 2.9M
  • Earning Date
  • IIF 01-01-0001
  • ALLO 08-06-2025
  • Dividend Yield
  • IIF 13.94%
  • ALLO N/A
  • EPS Growth
  • IIF N/A
  • ALLO N/A
  • EPS
  • IIF N/A
  • ALLO N/A
  • Revenue
  • IIF N/A
  • ALLO N/A
  • Revenue This Year
  • IIF N/A
  • ALLO N/A
  • Revenue Next Year
  • IIF N/A
  • ALLO $199.63
  • P/E Ratio
  • IIF N/A
  • ALLO N/A
  • Revenue Growth
  • IIF N/A
  • ALLO N/A
  • 52 Week Low
  • IIF $18.95
  • ALLO $0.86
  • 52 Week High
  • IIF $24.41
  • ALLO $3.78
  • Technical
  • Relative Strength Index (RSI)
  • IIF 62.45
  • ALLO 49.20
  • Support Level
  • IIF $27.91
  • ALLO $1.13
  • Resistance Level
  • IIF $28.30
  • ALLO $1.29
  • Average True Range (ATR)
  • IIF 0.29
  • ALLO 0.08
  • MACD
  • IIF -0.02
  • ALLO -0.00
  • Stochastic Oscillator
  • IIF 81.78
  • ALLO 50.00

About IIF Morgan Stanley India Investment Fund Inc.

Morgan Stanley India Investment Fund, Inc. is the United States based non-diversified, closed-end management investment company. Its investment objective is to achieve long-term capital appreciation through investment in equity securities of Indian Issuers. The company's portfolio of investments consists of the investment in different sectors such as auto components, banks, capital markets, construction and engineering, pharmaceuticals and others.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: